Less than a year after its founding, GammaDelta Therapeutics Ltd has received an investment from Takeda Pharmaceutical Company Ltd, which sees promise in the UK company’s T cell platform as a source for new immunotherapies. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals
